Belimumab

證據等級: L5

預測適應症: 6 個

Belimumab: From an Undocumented Original Indication to Primary Release Disorder of Platelets

One-Sentence Summary

The evidence pack does not contain Belimumab's original approved indication or mechanism of action (both flagged as data gaps). The TxGNN model predicts it may be effective for Primary Release Disorder of Platelets, but this direction is currently supported by only 1 clinical trial (assessed as not actually relevant to the predicted indication) and 0 publications.

Quick Overview

Item	Content
Original Indication	Not documented in evidence pack (data gap)
Predicted New Indication	Primary release disorder of platelets
TxGNN Prediction Score	99.96%
Evidence Level	L5 (model prediction only — the one associated trial is a label mismatch, not true supporting evidence)
Taiwan Market Status	未上市 (Not marketed)
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data for Belimumab is not available in this evidence pack, and no original indication is on file either — both are flagged as data gaps (DG001, DG002).

Based on the repurposing rationale that is available, the evidence pack itself concludes there is no known mechanistic link between Belimumab and primary release disorder of platelets: Belimumab is known to act on BAFF/BLyS signaling affecting B-cell survival and autoantibody production, a pathway unrelated to platelet granule release. The only associated clinical trial (NCT01610492) was reviewed and graded "C" — its actual subject was idiopathic membranous glomerulonephropathy, not a platelet disorder, and it was judged a database label mismatch rather than genuine supporting evidence.

Taken together, this prediction currently rests on the TxGNN model score alone, without a corroborating mechanistic hypothesis or relevant trial/literature evidence.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01610492	Phase 2	Completed	14	Studied belimumab in anti-PLA2R-positive idiopathic membranous glomerulonephropathy — not platelet-related; reviewer graded this a label mismatch and not valid supporting evidence for the predicted indication

Literature Evidence

Currently no related literature available.

Taiwan Market Information

Belimumab currently holds no marketing authorization in Taiwan (0 licenses on file; market status: 未上市).

Safety Considerations

Please refer to the package insert for safety information. Note: TFDA package insert warnings/contraindications data is flagged as a Blocking data gap (DG001) and must be obtained before any safety pre-assessment (S1) can proceed.

Conclusion and Next Steps

Decision: Hold

Rationale: Evidence level is L5 — the prediction is supported only by the TxGNN model score, with no confirmed mechanistic link and no relevant clinical trial or literature evidence (the single associated trial is a documented label mismatch). The drug is also not currently marketed in Taiwan, and safety data is a blocking gap.

To proceed, the following is needed:

TFDA package insert (warnings/contraindications) — resolve blocking gap DG001
Confirmed mechanism of action data — resolve gap DG002
Belimumab's original approved indication(s), for mechanistic comparison
Genuine clinical trial or literature evidence specific to primary release disorder of platelets (or a re-screen of the other 5 lower-ranked candidates, all of which are similarly at Hold/L5 with no supporting studies)
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.